Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Boston Scientific is a global medical device manufacturer specializing in interventional cardiology, electrophysiology, peripheral interventions, and neuromodulation. The company generates approximately 60% of revenue from cardiovascular products (drug-eluting stents, structural heart devices, electrophysiology catheters) and 40% from MedSurg (endoscopy, urology, neuromodulation), with strong market positions in high-growth segments like left atrial appendage closure (WATCHMAN) and pulsed field ablation. The stock trades on procedure volume growth, new product adoption cycles, and margin expansion from manufacturing scale.
Boston Scientific operates a razor-razorback model where capital equipment (EP mapping systems, endoscopy towers) drives recurring revenue from disposable catheters, guidewires, and accessories. The company commands premium pricing through clinical differentiation (FARAPULSE pulsed field ablation eliminates thermal injury risk vs RF ablation, WATCHMAN FLX has 90%+ LAA closure efficacy) and physician training/loyalty programs. Gross margins of 69% reflect high-value intellectual property, manufacturing scale in Costa Rica and Ireland facilities, and limited generic competition due to regulatory barriers (PMA approval timelines, clinical trial requirements). Operating leverage comes from spreading R&D and SG&A across growing procedure volumes, with recent margin expansion driven by portfolio mix shift toward higher-margin EP and structural heart products.
Cardiovascular procedure volumes in US hospitals - elective procedures (PCI, EP ablations, structural heart) drive 60% of revenue and are sensitive to hospital staffing, patient backlogs, and seasonal patterns
FARAPULSE pulsed field ablation adoption trajectory - launched Q4 2023, ramping toward $1B+ revenue potential with faster procedure times and safety profile vs thermal ablation driving EP market share gains
WATCHMAN FLX penetration in atrial fibrillation patients - 5M+ diagnosed AFib patients in US, current <10% penetration of addressable market, reimbursement expansion and OPTION trial data supporting growth
International revenue growth acceleration - China recovery post-VBP pricing pressure, Japan structural heart approvals, emerging market expansion contributing to 45% of total revenue
Gross margin trajectory - manufacturing efficiency gains, product mix shift toward higher-margin EP/structural heart, and pricing dynamics in competitive stent markets
Regulatory pathway lengthening and clinical trial cost inflation - FDA increasing scrutiny on cardiovascular devices post-safety concerns, requiring larger trials (WATCHMAN OPTION enrolled 1,600 patients) and longer follow-up periods, extending time-to-market and R&D costs
Reimbursement pressure from government and commercial payers - CMS proposing bundled payments for cardiovascular procedures, shifting risk to hospitals and potentially reducing device utilization; international VBP (volume-based procurement) in China forcing 30-50% price cuts on commodity products
Technology disruption risk from minimally invasive alternatives - pharmaceutical therapies (novel anticoagulants reducing WATCHMAN addressable market), AI-guided procedures reducing catheter usage, and robotic surgery platforms (Intuitive Surgical) potentially commoditizing device components
Intensifying competition in core EP market - Medtronic's Arctic Front cryoablation, Abbott's TactiFlex catheter, and J&J's Biosense Webster QDOT Micro competing directly with FARAPULSE; market share gains require sustained clinical evidence and physician training investment
Patent cliff exposure in drug-eluting stents - key Synergy and Onyx stent patents expiring 2027-2029, opening door to biosimilar competition and pricing pressure in $2B+ annual revenue category; requires portfolio shift toward differentiated structural heart and EP products to offset
Moderate leverage at 0.51 D/E with $8B+ gross debt - manageable given strong FCF generation, but rising rates increase refinancing costs as debt matures; interest expense of $300M+ annually reduces EPS by 8-10%
Acquisition integration risk - Boston Scientific pursues tuck-in M&A strategy (historically 1-2 deals annually in $500M-$2B range); execution risk on integrating technologies, retaining key personnel, and achieving revenue synergies; goodwill of $15B+ on balance sheet represents 40% of assets
moderate - Medical device procedures show resilience during recessions as cardiovascular interventions are often clinically necessary rather than purely elective. However, 20-30% of procedures (cosmetic urology, elective pain management) are deferrable during economic stress. Hospital capital equipment purchasing slows in downturns, affecting EP mapping system placements. Consumer sentiment impacts patient willingness to undergo elective procedures with out-of-pocket costs. Historical data shows medical device revenue declined only 5-10% during 2008-2009 vs 20%+ for discretionary healthcare services.
Rising rates have modest negative impact through two channels: (1) Hospital capital budgets tighten as borrowing costs increase, delaying equipment purchases and affecting procedure volumes in rate-sensitive health systems. (2) Valuation multiple compression - medical device stocks trade at premium P/E ratios (25-30x) and re-rate lower as risk-free rates rise, making growth less valuable. However, BSX's strong FCF generation ($2.4B annually) and moderate leverage (0.51 D/E) limit financing cost impact. The company benefits from fixed-rate debt structure with weighted average maturity of 10+ years.
Minimal direct credit exposure - revenue is primarily from hospitals and government payers (Medicare/Medicaid cover 60%+ of cardiovascular procedures) with low default risk. Indirect exposure exists through hospital financial health affecting capital spending and procedure volumes. Private equity-owned hospital chains with higher leverage may delay equipment upgrades during credit tightening. Accounts receivable quality remains strong with DSO in 60-70 day range. Credit spreads widening signals broader risk-off sentiment affecting growth stock valuations rather than fundamental credit risk to BSX operations.
growth - Boston Scientific attracts growth-oriented investors seeking exposure to aging demographics, cardiovascular disease prevalence, and medical technology innovation. The 20% revenue growth, 56% EPS growth, and expanding margins appeal to GARP (growth at reasonable price) investors. Recent 35% stock decline from highs creates entry point for long-term growth investors, though momentum investors have exited. Institutional ownership is high (90%+) with healthcare-focused funds and large-cap growth managers as core holders. Limited dividend yield (company does not pay dividend, focuses on reinvestment) makes it unsuitable for income investors.
moderate-high - Historical beta of 1.1-1.2 indicates slightly above-market volatility. Stock experiences 15-25% intra-quarter swings around earnings releases and FDA approval announcements. Recent 26% six-month decline reflects multiple compression across medical device sector and concerns about procedure volume normalization post-COVID surge. Volatility driven by quarterly earnings beats/misses (guidance revisions move stock 5-10%), clinical trial readouts (positive data can drive 8-12% single-day moves), and M&A speculation. Options market implies 25-30% annualized volatility, above healthcare sector average of 20%.
